【摘要】 目的研究乳腺癌新辅助化疗过程中原发灶变化的趋势。方法自2013年12月~2015年1月中选取19例患者接受6周期多西他赛+表柔比星+环磷酰胺(TEC)方案新辅助化疗,每2周期评价化疗效果,研究肿块变化的趋势。结果 19例患者6周期新辅助化疗后,达到CR患者3例(15.8%),PR患者11例(57.9%),SD患者5例(26.3%),有效例数CR+PR为14(73.7%),PCR患者3例(15.8%)。新辅助化疗过程中各组间肿块大小存在相关性(P=0.04<0.05),乳腺癌肿块大小随着新辅助化疗周期呈逐渐缩小的趋势(P<0.05)。结论随着TEC方案化疗周期的延长,原发灶呈逐渐缩小的趋势,可能获得更高的PCR率和保乳率。更多还原

【Abstract】 Objective To study the situation of primary tumor after receiving the neoadjuvant chemotherapy in breast cancer. Methods Chose 19 patients that had received 6 cycles of docetaxel combined with epirubicin, cyclophosphamide anthracycline neoadjuvant chemotherapy from Dec 2013 to Jan 2015. They were evaluated for chemotherapy effect per 2 cycles. The change trend of lump was studied. Results After 6 cycles of neoadjuvant chemotherapy 19 cases,the effect of chemotherapy of CR 3 cases(15.8%), PR 11 cases(57.9%), SD 5 cases(26.3%), and CR+PR 14 cases(73.7%), PCR 3 cases(15.8%). The lump size of each group was associated with the process of neoadjuvant chemotherapy(P=0.04<0.05) and it had a tendency to shrink(P<0.05). Conclusion With the extension of TEC chemotherapy cycles, primary tumor size shows a decreasing trend. The patients may get higher rates of PCR and breast conserving.更多还原